Laboratory diagnostics technology developer Sysmex (Kobe, Japan) has entered into a clinical research, joint development, and licensing agreement with EMD Millipore (Billerica, MA) involving EMD Millipore's imaging flow cytometry technology. The collaboration aims to use EMD Millipore’s technology as a platform to accelerate the creation of new, more powerful diagnostic tools. If successful, the two companies will collaborate on developing an imaging flow cytometry platform for future commercialization in hematology.
Related: Future cytometry: Going with—or without—the flow
Sysmex has developed various products to analyze cells within the blood, using flow cytometry as a platform that can be easily deployed in a clinical setting.
The agreement involves imaging flow cytometry technology developed by Amnis, which was acquired by EMD Millipore in 2011. The technology platform combines the power of flow cytometry with rapid capture of high-volume images of cell morphology, fluorescence imaging, and automated digital image analysis. The clinical study will assess the use of imaging flow cytometry technology as a platform for diagnosing hematologic disorders such as leukemia.
Once clinical research is complete, the two companies intend to develop more powerful diagnostic tools that will generate image data of molecular (protein) expression status, as well as the identification of abnormal cells in the blood. Sysmex aims to promote the creation of new diagnostic technologies that will enable the realization of personalized medicine and contribute to the advancement of healthcare by meeting increasingly diverse and sophisticated testing needs.
Follow us on Twitter, 'like' us on Facebook, and join our group on LinkedIn
Subscribe now to BioOptics World magazine; it's free!